Mounjaro and Zepbound's label carries a warning for acute gallbladder disease. A 2025 meta-analysis of 12 trials put a number on that risk — here's what it found, and what it didn't.
Tirzepatide's prescribing information lists "Acute Gallbladder Disease" as a warning and precaution, separate from its more familiar gastrointestinal side effects like nausea and diarrhea. The label instructs that if cholecystitis is suspected, gallbladder studies and clinical follow-up are indicated.
The mechanism isn't mysterious. Rapid weight loss itself raises gallstone risk, independent of the drug used to get there — it's a well-documented effect of bariatric surgery and very-low-calorie diets alike. On top of that, GLP-1 receptor activation appears to suppress cholecystokinin, a hormone that helps the gallbladder empty, and GIP receptor activation may relax the gallbladder further. Because tirzepatide acts on both receptors and produces faster, larger weight loss than older GLP-1 drugs, researchers have asked whether its gallbladder signal is larger too.
Published in the Journal of Diabetes Investigation in January 2025, the analysis pooled 12 high-quality randomized controlled trials totaling 12,351 patients with type 2 diabetes or obesity, comparing tirzepatide against placebo, insulin, dulaglutide, or semaglutide over 12 to 72 weeks.
Both significant findings held with low heterogeneity across studies (I² = 0%), meaning the trials largely agreed with each other. Oddly, the risk didn't climb with dose — the 5 mg dose showed the clearest association with both gallbladder disease and gallstones, while 10 mg and 15 mg did not reach statistical significance on their own, though the authors note some of those subgroups had too few events to detect a real effect reliably.
Across 12 trials and over 12,000 patients, tirzepatide raised the risk of gallbladder or biliary disease by about 50% and gallstones specifically by about two-thirds, versus placebo or other diabetes drugs. Pancreatitis and cholecystitis alone were not significantly elevated — the signal is specific to gallstone formation, not broader biliary inflammation.
Sources: Gong et al., "Risk of biliary diseases in patients with type 2 diabetes or obesity treated with tirzepatide: A meta-analysis," Journal of Diabetes Investigation, 2025 (DOI 10.1111/jdi.14340) — read the full study. FDA prescribing information for Zepbound (tirzepatide), Section 5.4, Acute Gallbladder Disease — full label (accessdata.fda.gov).
Know the symptoms of a gallstone problem — sudden, steady pain in the upper right abdomen or between the shoulder blades, often after a fatty meal, sometimes with nausea or fever. That's different from the day-or-two GI upset that follows a dose increase, and it's worth calling your prescriber about rather than waiting it out.
The risk applies broadly to rapid weight loss, not just this drug — losing weight quickly by any method raises gallstone odds. Tirzepatide's effect on top of that appears real but modest at the individual level; most people on the drug will never develop a gallbladder problem.
This isn't a reason to avoid tirzepatide if you and your prescriber have already decided it's right for you — it's a reason to recognize the symptoms early, since untreated gallstones can progress to more serious complications.
This article summarizes a published meta-analysis and FDA prescribing information for general education. It is not medical advice and does not replace guidance from your prescriber. If you develop persistent abdominal pain while taking tirzepatide, contact your healthcare provider promptly.